Cantargia AB (publ)
CANTA
Rank in Stocks
#23212
Cantargia AB (publ), a biotechnology company established in Lund, Sweden, in... Cantargia AB (publ), a biotechnology company established in Lund, Sweden, in 2010, is dedicated to the research and development of antibody-driven therapies for severe illnesses. Its lead product, CAN04, is an antibody specifically engineered to target Interleukin-1 Receptor Accessory Protein (IL1RAP). This innovative treatment aims to identify and stimulate the immune system to destroy cancer cells, while also mitigating tumor-related inflammation fueled by the Interleukin-1 system, and is currently in Phase IIa clinical trials. The company is also advancing CAN10, another IL1RAP-specific antibody, through preclinical development for autoimmune and inflammatory conditions like systemic sclerosis and myocarditis. Additionally, Cantargia is exploring other CANxx antibodies that also interact with IL1RAP. The manufacturing and production of CAN04 are facilitated through partnerships with Patheon Biologics BV and BioWa Inc., and its clinical study is supported by Specialized Medical Services-oncology BV.
Share Price
$0.15783444
Last synced: 2026-11-09
Market Cap
$44.50M
Change (1 day)
-2.73%
Change (1 year)
-58.76%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Cantargia AB (publ) (CANTA)
Category
Healthcare
EPS for Cantargia AB (publ) (CANTA)
EPS as of June 2026 TTM: $0.07
According to Cantargia AB (publ)'s latest financial reports, its current EPS (TTM) is $0.07. At the end of 2025 the company had an EPS of $0.06, an increase over its 2024 EPS of $-0.08.
EPS history for Cantargia AB (publ) from 2011 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $0.07 | 14.33% |
| 2025 | $0.06 | -180.08% |
| 2024 | $-0.08 | -51.22% |
| 2023 | $-0.16 | -41.17% |
| 2022 | $-0.28 | -31.23% |
| 2021 | $-0.40 | 107.60% |
| 2020 | $-0.19 | 39.84% |
| 2019 | $-0.14 | 8.24% |
| 2018 | $-0.13 | -32.12% |
| 2017 | $-0.19 | -19.11% |
| 2016 | $-0.23 | 97.64% |
| 2015 | $-0.12 | 88.85% |
| 2014 | $-0.06 | -13.97% |
| 2013 | $-0.07 | 137.79% |
| 2012 | $-0.03 | 5.86% |
| 2011 | $-0.03 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | 22,727.99% |
US
|
|
| $-7.07 | -10,406.12% |
US
|
|
| $-5.29 | -7,811.37% |
AU
|
|
| $12.88 | 18,675.66% |
BE
|
|
| $21.56 | 31,328.57% |
NL
|
Questions about Cantargia AB (publ)'s earnings per share (EPS)
What is Cantargia AB (publ)'s earnings per share (EPS)?
Cantargia AB (publ)'s earnings per share (EPS) over the last twelve months is $0.07, as of Jun 2026.
What was Cantargia AB (publ)'s earnings per share (EPS) in 2025?
In 2025, Cantargia AB (publ)'s earnings per share (EPS) was $0.06, compared with $-0.08 in 2024.
How has Cantargia AB (publ)'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Cantargia AB (publ)'s earnings per share (EPS) was highest in 2025 ($0.06) and lowest in 2021 ($-0.40).
How does Cantargia AB (publ)'s earnings per share (EPS) compare with similar companies?
Cantargia AB (publ)'s earnings per share (EPS) ($0.07) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.